Last month, it was announced that two new drugs were approved by the US Food and Drug Administration, for treatment of Parkinson’s disease (PD). Both drugs, Rytary™ and Duopa™, are updates to carbidopa/levodopa. They offer, respectively, a newer formulation and delivery method to reduce off-times for those with PD. In this Q&A, PDF speaks with Myra Hirschhorn, one of our trained Research Advocates, to understand the community reaction to the approvals. As part of the Parkinson’s Advocates in Research program, Myra has been trained in the drug development process, and educates her community about research.
The start of 2015 has been noteworthy for those with Parkinson’s disease (PD) as two new therapies – Rytary™ and Duopa™ – were approved by the FDA at the start of January. Both therapies are updates to the gold-standard treatment of carbidopa/levodopa for those with PD. Manufacturers of both therapies hope to have the medications available on pharmacy shelves in the next few months. Yes, carbidopa/levodopa first came into use around 1970. However, these new therapies address a real need that current carbidopa/levodopa or Sinemet cannot meet … and that is good news. PDF has covered what Rytary and Duopa are (check out my… Read More
When 30,000 neuroscientists gather together to talk about the brain, what can we learn about Parkinson’s disease? Our team found out at the latest meeting of the Society for Neuroscience (SfN) meeting in Washington, DC, which took place in November. At the meeting, PDF’s James Beck, Ph.D., VP for Scientific Affairs, and Beth Vernaleo, Ph.D., Senior Manager, Research Programs, were joined by PDF Research Advocates Todd Hebb and Paul Zimmet, D.D.S., both of whom live with PD. (Drs. Zimmet and Vernaleo are pictured inset).
Thank you, on behalf of the Board of Directors, for those of you who have supported the Parkinson’s Disease Foundation this year, including those who have donated to this month’s special $500,000 challenge. Because of you, we have raised over $150,000 so far toward our goal, and every single gift will be doubled. As a scientist, your support gives me hope. I spent many years working with the nation’s largest biomedical research agency, the National Institutes of Health (NIH), to award billions of dollars in grants for neuroscience research, including Parkinson’s. And I knew of PDF’s reputation for supporting the next generation of… Read More
In this Q&A, Diane Cook shares her experience being involved in the PDF Community Choice Research Award. Last year, PDF launched the award by asking the community, “what is the most pressing question for scientists to solve in PD?” From the hundreds of submissions we received, our advisory board selected two – fatigue and gastrointestinal function – for awards. This fall, we’re hosting conferences to outline solutions for both symptoms. Q. You attended the first ever conference funded by the PDF Community Choice Research Award. What are your overall impressions? A. First of all, it was very exciting to be… Read More
In this Q&A, Anne Newbould, a care partner to her husband with PD, shares her experience being involved in the PDF Community Choice Research Award. Last year, when PDF launched the award by asking, “what is the most pressing question for scientists to solve in PD?” she answered: fatigue. Her research priority was selected from amongst hundreds of submissions. This week, to address the symptom she helped to identify, PDF is bringing together experts and advocates in Chicago, IL. Q. What motivated you to submit your research idea for PDF’s Community Choice Research Award? A. My husband of over 40 years, James, has… Read More